Investigational drug · Phase 3
COYA 302
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Amyotrophic Lateral Sclerosis (ALS).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "COYA 302"
First trial start
2025
Oct 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "COYA 302", any sponsor or status.
Conditions studied
As listed on its trial records.
- Amyotrophic Lateral Sclerosis (ALS)
Approved drugs for the same conditions: ALS (amyotrophic lateral sclerosis) · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "COYA 302" as an intervention, largest first.
- Study of COYA 302 for the Treatment of ALSPivotal-lookingActive, not recruiting
Coya TherapeuticsIndustry
NCT07161999 · 120 participants (planned) · Start Oct 1, 2025 · Primary completion Apr 2027
Drug: COYA 302; Placebo · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Phoenix, Arizona; Los Angeles, California; San Francisco, California · 25 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Amyotrophic Lateral Sclerosis (ALS)
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- ALT001Phase 22 trials
Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. · Ischemic Stroke in the Sequelae Stage, Amyotrophic Lateral Sclerosis (ALS)
- VHB937Phase 22 trials
Novartis · Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease
- FHND1002Phase 21 trial
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Amyotrophic Lateral Sclerosis (ALS)
- NB-4746Phase 21 trial
Nura Bio · Amyotrophic Lateral Sclerosis (ALS)
- SNUG01Phase 21 trial
SineuGene Therapeutics Co., Ltd. · Amyotrophic Lateral Sclerosis (ALS)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.